139 related articles for article (PubMed ID: 38293699)
1. Tislelizumab plus nimotuzumab is effective against recurrent or metastatic oral squamous cell carcinoma among patients with a performance status score ≥ 2: a retrospective study.
Wu WJ; An PG; Zhong YW; Hu X; Wang L; Zhang J
Front Oncol; 2023; 13():1273798. PubMed ID: 38293699
[TBL] [Abstract][Full Text] [Related]
2. [Tislelizumab monotherapy for the treatment of recurrent/metastatic head and neck squamous cell carcinoma].
Song P; Liang F; Ye Y; Huang Y; Wu T; Huang X; Han P
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2023 Oct; 37(10):778-785. PubMed ID: 37828879
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of nimotuzumab in unresectable, recurrent, and/or metastatic squamous cell carcinoma of the head and neck: A hospital-based retrospective evidence.
Subramanian S; Sridharan N; Balasundaram V; Chaudhari S
South Asian J Cancer; 2018; 7(3):188-192. PubMed ID: 30112336
[TBL] [Abstract][Full Text] [Related]
4. SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.
Zhao J; Yu X; Huang D; Ma Z; Gao B; Cui J; Chu Q; Zhou Q; Sun M; Day D; Wu J; Pan H; Wang L; Voskoboynik M; Wang Z; Liu Y; Li H; Zhang J; Peng Y; Wu YL
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36808075
[TBL] [Abstract][Full Text] [Related]
5. Response to nivolumab combining radiotherapy and nimotuzumab in metastatic oral squamous cell carcinoma patient with strong PD-L1 expression: a case report.
Tang X; Chen S; Sui Q; Li X; Liu Z; Zhu F; Ding J; Yao Y; Jiang B; He Y
Ann Transl Med; 2020 Mar; 8(6):402. PubMed ID: 32355846
[TBL] [Abstract][Full Text] [Related]
6. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
7. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Wang J; Lu S; Yu X; Hu Y; Sun Y; Wang Z; Zhao J; Yu Y; Hu C; Yang K; Feng G; Ying K; Zhuang W; Zhou J; Wu J; Leaw SJ; Zhang J; Lin X; Liang L; Yang N
JAMA Oncol; 2021 May; 7(5):709-717. PubMed ID: 33792623
[TBL] [Abstract][Full Text] [Related]
8. Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
Xu J; Bai Y; Xu N; Li E; Wang B; Wang J; Li X; Wang X; Yuan X
Clin Cancer Res; 2020 Sep; 26(17):4542-4550. PubMed ID: 32561664
[TBL] [Abstract][Full Text] [Related]
9. Combined Nimotuzumab with Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
Thai Hoa NT; Quang Huy H
Cureus; 2020 May; 12(5):e8105. PubMed ID: 32426197
[TBL] [Abstract][Full Text] [Related]
10. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
Shen L; Kato K; Kim SB; Ajani JA; Zhao K; He Z; Yu X; Shu Y; Luo Q; Wang J; Chen Z; Niu Z; Zhang L; Yi T; Sun JM; Chen J; Yu G; Lin CY; Hara H; Bi Q; Satoh T; Pazo-Cid R; Arkenau HT; Borg C; Lordick F; Li L; Ding N; Tao A; Shi J; Van Cutsem E;
J Clin Oncol; 2022 Sep; 40(26):3065-3076. PubMed ID: 35442766
[TBL] [Abstract][Full Text] [Related]
11. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D;
Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945
[TBL] [Abstract][Full Text] [Related]
13. Overall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Nimotuzumab in the Real World.
Saumell Y; Sanchez L; González S; Ortiz R; Medina E; Galán Y; Lage A
Adv Ther; 2017 Dec; 34(12):2638-2647. PubMed ID: 29134427
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma.
Hong MH; Heo SG; Lee YG; Kim HS; Park KU; Kim HG; Ko YH; Chung IJ; Min YJ; Kim MK; Kim KR; Yoo J; Kim TM; Kim HR; Cho BC
Cancer; 2020 Oct; 126(20):4521-4531. PubMed ID: 32749686
[TBL] [Abstract][Full Text] [Related]
15. Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma.
Ye D; Liu J; Zhou A; Zou Q; Li H; Fu C; Hu H; Huang J; Zhu S; Jin J; Ma L; Guo J; Xiao J; Park SH; Zhang D; Qiu X; Bao Y; Zhang L; Shen W; Bi F
Cancer Sci; 2021 Jan; 112(1):305-313. PubMed ID: 33047430
[TBL] [Abstract][Full Text] [Related]
16. Anti-PD-1 Monoclonal Antibody Combined With Anti-VEGF Agent Is Safe and Effective in Patients With Recurrent/Metastatic Head and Neck Squamous Cancer as Second-Line or Beyond Treatment.
Hua Y; Dong R; Jin T; Jin Q; Chen X
Front Oncol; 2022; 12():781348. PubMed ID: 35280787
[TBL] [Abstract][Full Text] [Related]
17. Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial.
Lu S; Wang J; Yu Y; Yu X; Hu Y; Ai X; Ma Z; Li X; Zhuang W; Liu Y; Li W; Cui J; Wang D; Liao W; Zhou J; Wang Z; Sun Y; Qiu X; Gao J; Bao Y; Liang L; Wang M
J Thorac Oncol; 2021 Sep; 16(9):1512-1522. PubMed ID: 34033975
[TBL] [Abstract][Full Text] [Related]
18. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
[TBL] [Abstract][Full Text] [Related]
19. Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.
Wang H; Mao L; Zhang T; Zhang L; Wu Y; Guo W; Hu J; Ju H; Ren G
J Oral Pathol Med; 2019 Sep; 48(8):669-676. PubMed ID: 31132187
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
